Boston, Mass., August 13, 2015 – To support its growing program on new drug assessment, the Institute for Clinical and Economic Review (ICER) has expanded its staff to include additional expertise in health policy, health economics, systematic reviews, communications, and operations. ICER recently announced a transformative grant to expand its scope and grow its staff. These hires represent phase one of that expansion.
“The wide variety of backgrounds and skills of our new team members will serve to strengthen ICER as we continue to grow,” stated Steven D. Pearson, MD, MSc, ICER’s Founder and President. ”Each of these new employees is poised to make a meaningful and immediate contribution to ICER as we conduct our analysis of comparative effectiveness, cost-effectiveness, and potential budget impact of new drugs and other medical services.”
The new employees include (each name links to full bio):
Also in July, ICER’s Chief Review Officer, Dan Ollendorf, PhD, was appointed to the Medicare Evidence Development & Coverage Advisory Committee (MEDCAC). MEDCAC was created to provide independent guidance and expert advice to the Centers for Medicare and Medicaid Services (CMS) on specific clinical topics. As ICER’s Chief Review Officer he is responsible for the conduct of systematic reviews of the comparative effectiveness of new or emerging health care technologies, as well as the coordination and oversight of the broader health technology assessment process.
Dr. Pearson noted: “I’m thrilled that Dan has received the well-deserved honor of being asked to serve on MEDCAC. It is a reflection of Dan’s stature in the evidence review community and his invaluable contributions to the field of comparative effectiveness research while here at ICER.”
ICER still has several positions available in epidemiology, economics and project management. Please visit the Careers section of our website for more information.